Table 3 Patient characteristics at each assessment point
From: Shared decision-making in antihypertensive therapy: a cluster randomised controlled trial
Intervention group | Control group | |||||||
|---|---|---|---|---|---|---|---|---|
T0 | T1 | T2 | T3 | T0 | T1 | T2 | T3 | |
Number GP practices | 17 | 17 | 17 | 17 | 19 | 19 | 18 | 18 |
Primary endpoints | ||||||||
SDM-Q-9 | ||||||||
Total valid Nr | 451 | 363 | 333 | 301 | 489 | 368 | 295 | 269 |
Mean | 73.00 | 73.03 | 70.51 | 71.71 | 70.67 | 66.55 | 67.20 | 66.60 |
(SD) | (17.66) | (19.54) | (20.98) | (20.59) | (20.24) | (21.34) | (20.00) | (20.71) |
Systolic BP | ||||||||
Total valid N | 552 | 463 | 418 | 383 | 568 | 457 | 394 | 348 |
Mean in mmHg | 133.19 | 128.86 | 129.27 | 128.68 | 130.80 | 126.98 | 126.62 | 125.98 |
(SD) | (13.58) | (12.51) | (12.80) | (11.42) | (12.62) | (11.75) | (12.29) | (11.23) |
Secondary endpoints | ||||||||
Diastolic BP | ||||||||
Total valid N | 552 | 463 | 418 | 383 | 568 | 457 | 394 | 348 |
Mean in mmHg | 81.98 | 79.21 | 79.07 | 78.55 | 79.29 | 76.75 | 76.75 | 75.64 |
(SD) | (9.77) | (9.49) | (8.79) | (8.81) | (9.74) | (9.10) | (9.10) | (8.46) |
CVR | ||||||||
Total valid N | 420 | 364 | 320 | 312 | 377 | 336 | 270 | 233 |
Mean in % | 20.40 | 21.02 | 22.33 | 23.92 | 22.85 | 23.54 | 24.03 | 24.34 |
(SD) | (18.15) | (18.61) | (18.82) | (19.10) | (18.71) | (19.19) | (19.23) | (19.60) |
MARS-D | ||||||||
Total valid N | 531 | 419 | 387 | 349 | 539 | 408 | 357 | 326 |
Mean | 93.9 | 95.4 | 96.0 | 96.1 | 93.5) | 96.0 | 96.1 | 95.3 |
(SD) | (9.8) | (8.8) | (6.8) | (8.0) | (10.1) | (6.3) | (6.8) | (7.5) |
Knowledge | 536 | 455 | 412 | 371 | 547 | 444 | 382 | 343 |
Total valid N | 536 | 455 | 412 | 371 | 547 | 444 | 382 | 343 |
Mean | 46.63 | 50.05 | 50.18 | 53.34 | 44.22 | 47.04 | 47.64 | 48.51 |
(SD) | (27.60) | (28.39) | (28.32) | (28.21) | (28.64) | (30.11) | (30.49) | (30.15) |